NASDAQ:APTO Aptose Biosciences (APTO) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free APTO Stock Alerts $1.66 +0.16 (+10.67%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.50▼$1.7050-Day Range$1.40▼$2.2052-Week Range$1.36▼$9.90Volume136,730 shsAverage Volume91,949 shsMarket Capitalization$26.10 millionP/E RatioN/ADividend YieldN/APrice Target$19.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Aptose Biosciences alerts: Email Address Aptose Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,092.8% Upside$19.80 Price TargetShort InterestHealthy0.54% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 13 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.65 out of 5 starsMedical Sector437th out of 938 stocksBiological Products, Except Diagnostic Industry64th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingAptose Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.80, Aptose Biosciences has a forecasted upside of 1,092.8% from its current price of $1.66.Amount of Analyst CoverageAptose Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.54% of the float of Aptose Biosciences has been sold short.Short Interest Ratio / Days to CoverAptose Biosciences has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptose Biosciences has recently decreased by 28.69%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAptose Biosciences does not currently pay a dividend.Dividend GrowthAptose Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APTO. Previous Next 2.9 News and Social Media Coverage News SentimentAptose Biosciences has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Aptose Biosciences this week, compared to 1 article on an average week.Search Interest4 people have searched for APTO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows4 people have added Aptose Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aptose Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.53% of the stock of Aptose Biosciences is held by insiders.Percentage Held by InstitutionsOnly 26.62% of the stock of Aptose Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Aptose Biosciences is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aptose Biosciences is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAptose Biosciences has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Aptose Biosciences Stock (NASDAQ:APTO)Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Read More APTO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APTO Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comAptose Biosciences (NASDAQ:APTO) Given Buy Rating at HC WainwrightMarch 28, 2024 | finanznachrichten.deAptose Biosciences, Inc.: Aptose Reports Results for the Fourth Quarter and Full Year 2023March 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 27, 2024 | finance.yahoo.comAptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | msn.comEdgewood secures $20m in Series A for clinical development of cancer therapyMarch 27, 2024 | benzinga.comRecap: Aptose Biosciences Q4 EarningsMarch 26, 2024 | globenewswire.comAptose Reports Results for the Fourth Quarter and Full Year 2023March 24, 2024 | americanbankingnews.comAptose Biosciences (APTO) to Release Quarterly Earnings on TuesdayMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 23, 2024 | americanbankingnews.comAptose Biosciences Inc. (NASDAQ:APTO) Receives Average Rating of "Buy" from BrokeragesMarch 19, 2024 | americanbankingnews.comAptose Biosciences (NASDAQ:APTO) Downgraded by StockNews.com to SellMarch 18, 2024 | globenewswire.comAptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024January 29, 2024 | finance.yahoo.comThis Aptose Biosciences Insider Increased Their Holding In The Last YearJanuary 26, 2024 | marketwatch.comAptose Biosciences Shares Drop 11% After Private, Public OfferingsJanuary 26, 2024 | markets.businessinsider.comAptose Prices Offering Of About 4.91 Mln Shares At $1.71/Share, $4 Private Placement With HanmiJanuary 26, 2024 | finance.yahoo.comAptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi PharmaceuticalJanuary 26, 2024 | investorplace.comWhy Is Aptose Biosciences (APTO) Stock Down Today?December 21, 2023 | benzinga.comAptose Biosciences Stock (NASDAQ:APTO), Guidance and ForecastDecember 5, 2023 | morningstar.comAptose Biosciences Inc APTODecember 4, 2023 | msn.comAptose Biosciences files to sell ordinary shares, warrantsDecember 1, 2023 | finanznachrichten.deAptose Biosciences, Inc.: Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive RoleNovember 12, 2023 | seekingalpha.comAptose Biosciences Inc. (APTO) Q3 2023 Earnings Call TranscriptNovember 11, 2023 | benzinga.comAptose Biosciences Stock (NASDAQ:APTO) Earnings Dates and Earning CallsNovember 10, 2023 | benzinga.comAptose Biosciences: Q3 Earnings InsightsNovember 10, 2023 | markets.businessinsider.comPromising Financial Performance and Clinical Developments Bolster Aptose Biosciences’ Buy Rating: An Analysis by Joseph PantginisNovember 9, 2023 | msn.comAptose Biosciences GAAP EPS of -$1.76 beats by $0.22November 1, 2023 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Aptose Biosciences (APTO)See More Headlines Receive APTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/23/2023Today3/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:APTO CUSIPN/A CIK882361 Webwww.aptose.com Phone858-926-2730Fax905-234-2120Employees31Year FoundedN/APrice Target and Rating Average Stock Price Target$19.80 High Stock Price Target$38.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,220.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($7.7189) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-323.04% Return on Assets-177.02% Debt Debt-to-Equity RatioN/A Current Ratio1.59 Quick Ratio1.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.13 per share Price / Book0.24Miscellaneous Outstanding Shares15,720,000Free Float14,220,000Market Cap$23.58 million OptionableNo Data Beta1.30 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. William G. Rice Ph.D. (Age 59)Chairman, Pres & CEO Mr. Gregory K. Chow CPA (Age 45)MBA, BA, Sr. VP, CFO & Principal Accounting Officer Mr. Ernest Kitt B.S.M.S, VP of Devel. & Technical OperationsDr. Stephen B. Howell (Age 73)Chief Medical Officer Mr. Peter MurrayDirector of Clinical Devel.Key CompetitorsSurrozenNASDAQ:SRZNZIVO BioscienceNASDAQ:ZIVOSAB BiotherapeuticsNASDAQ:SABSAIM ImmunoTechNYSE:AIMPharmaCyte BiotechNASDAQ:PMCBView All CompetitorsInsiders & InstitutionsNantahala Capital Management LLCSold 16,351 shares on 2/15/2024Ownership: 0.802%Citadel Advisors LLCBought 44,522 shares on 2/15/2024Ownership: 0.413%Texas Capital Bank Wealth Management Services IncBought 12,448 shares on 2/8/2024Ownership: 0.157%Sigma Planning CorpSold 70,309 shares on 2/1/2024Ownership: 0.951%Bernd R SeizingerBought 17,000 shares on 9/22/2023Total: $53,380.00 ($3.14/share)View All Insider TransactionsView All Institutional Transactions APTO Stock Analysis - Frequently Asked Questions Should I buy or sell Aptose Biosciences stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" APTO shares. View APTO analyst ratings or view top-rated stocks. What is Aptose Biosciences' stock price target for 2024? 5 Wall Street research analysts have issued 12-month price targets for Aptose Biosciences' stock. Their APTO share price targets range from $5.00 to $38.00. On average, they anticipate the company's stock price to reach $19.80 in the next year. This suggests a possible upside of 1,092.8% from the stock's current price. View analysts price targets for APTO or view top-rated stocks among Wall Street analysts. How have APTO shares performed in 2024? Aptose Biosciences' stock was trading at $2.54 at the beginning of the year. Since then, APTO shares have decreased by 34.6% and is now trading at $1.66. View the best growth stocks for 2024 here. Are investors shorting Aptose Biosciences? Aptose Biosciences saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 50,200 shares, a decrease of 28.7% from the February 29th total of 70,400 shares. Based on an average trading volume of 93,300 shares, the short-interest ratio is presently 0.5 days. Approximately 0.5% of the company's shares are short sold. View Aptose Biosciences' Short Interest. When is Aptose Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our APTO earnings forecast. How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (NASDAQ:APTO) posted its quarterly earnings data on Thursday, March, 23rd. The biotechnology company reported ($1.65) EPS for the quarter, hitting analysts' consensus estimates of ($1.65). During the same period last year, the company posted ($4.05) earnings per share. When did Aptose Biosciences' stock split? Aptose Biosciences's stock reverse split on the morning of Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO? 8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX). Who are Aptose Biosciences' major shareholders? Aptose Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Nantahala Capital Management LLC (0.80%), Sigma Planning Corp (0.95%), Citadel Advisors LLC (0.41%), Texas Capital Bank Wealth Management Services Inc (0.16%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bernd R Seizinger, Denis R Burger, Donald R Jr Wilson, Erich Platzer, Rafael Bejar, Warren Whitehead and William G Rice. View institutional ownership trends. How do I buy shares of Aptose Biosciences? Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:APTO) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry Research“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.